Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

February 12, 2008
Low Molecular Weight Heparins (LMWH): a windfall!!
By a GLG Expert Contributor
Analysis of: Problems in Blood Drug Lead to Halt by Factory (www.nytimes.com)
If there is a production delay in "standard" heparin, it will open the door for LMWH preparations. Which ones? Sanofi-Aventis's Lovenox
February 11, 2008
Are second (tandem) transplants dead in MM and what does it mean to PHARMA
By a GLG Expert Contributor
Analysis of: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial (bloodjournal.hematologylibrary.org)
Thalidomide post single stem cell transplant is as good as two transplants back to back (tandem.)
February 11, 2008
Hair follicle analysis directing cancer care- What if the chemo or mother nature leaves you bald???
By a GLG Expert Contributor
Analysis of: Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development (www.foxbusiness.com)
Analysis of RNA obtained from hair follicles can be used to guide drug development and therapy
February 8, 2008
Diabetes Mellitus Trial: Disclaimer: I am not a diabetes expert but I have been a physician x 39 years....
By a GLG Expert Contributor
Analysis of: Diabetes Study Partially Halted After Deaths (www.nytimes.com)
".... a major federal study of more than 10,000 middle-aged and older people with Type 2 diabetes (DM) has found that lowering blood sugar actually increased their risk of death, researchers reported Wednesday."
February 5, 2008
GlaxoSmithKline (GSK) oral Topotecan: Impact? Use?
By a GLG Expert Contributor
Analysis of: GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer (www.pipelinereview.com)
An oral version of Topotecan that can be used 2nd line in SCLCA. Impact?
February 4, 2008
Velcade: 1st line indication probable, but is it really better and easier??
By a GLG Expert Contributor
Analysis of: FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma (www.pipelinereview.com)
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) is pressing for approval of Velcade in a first line rather than second line + setting. This would definitely increase sales
February 1, 2008
Lung Cancer: Make way for Sutent (Pfizer)
By a GLG Expert Contributor
Analysis of: Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer (jco.ascopubs.org)
Preliminarily appears to be effective in Non Small Cell Carcinoma of the Lung (NSCLCA). Overall response rates are comparable to standard second line agent efficacy, and its ORAL.
January 31, 2008
Statins: I Knew It, I Knew It, I Knew It......
By a GLG Expert Contributor
Analysis of: Great Drug, but Does It Prolong Life? (www.nytimes.com)
For people without cardiovascular disease or > 70 there is no benefit to statins!!!!
January 30, 2008
Panzem and Avastin Active in Carcinoid Tumors? I'm not so sure....
By a GLG Expert Contributor
Analysis of: EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study (www.pipelinereview.com)
Panzem is an oral formulation of 2-methoxyestradiol with multiple anti-tumor actions. These include tubulin disruption to halt mitosis (cell division), apoptosis stimulation and, similarly to Avastin (bevacizumab), angiogenesis inhibition.      87% of patients had stable disease...
January 29, 2008
Roche Holding AG : Avastin in the EU receives approval for wider applicability
By a GLG Expert Contributor
Analysis of: Roche's Avastin Cleared For Wider Use in the EU (online.wsj.com)
Avastin was approved for wider use in the EU with multiple chem agents including Roche's Xeloda (Can you say synergy?)

Previous Page : 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next171 to 180 of 456

Analytics


Generated at 2009-01-07T07:00:32.297